Valuation: TapImmune Inc

Market Cap 20.51M 17.81M 16.6M 15.25M 28.85M 1.95B 29.16M 196M 76.52M 975M 77.01M 75.33M 3.23B P/E 2026 *
-1.28x
P/E 2027 * -1.21x
Enterprise Value 20.51M 17.81M 16.6M 15.25M 28.85M 1.95B 29.16M 196M 76.52M 975M 77.01M 75.33M 3.23B EV / Sales 2026 *
7.25x
EV / Sales 2027 * 1.02x
Free-Float
94.51%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 46 01/05/2023
Chief Operating Officer 36 01/12/2023
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 46 17/10/2018
Chairman 65 24/05/2022
Director/Board Member 62 06/08/2019
Change 5-day change 1-year change 3-year change Capi.($)
+4.17%-12.24% - - 20.51M
+0.36%-2.85%+0.14%+13.91% 48B
+0.54%+7.31%+405.70%+554.99% 41.13B
+2.61%-5.24%+27.54%+6.97% 37.56B
+2.22%+0.74%+7.29%+75.78% 35.91B
+2.42%+7.27%+14.90%+44.79% 29.86B
-0.20%-2.66% - - 16.12B
+1.10%-0.61%+33.25%+123.26% 16.05B
+1.25%+1.52%+4.62%+18.66% 13.76B
+4.14%-7.93%-1.16%-34.79% 12.1B
Average +1.87%-2.15%+61.54%+100.45% 27.83B
Weighted average by Cap. +1.50%-1.29%+81.14%+126.42%

Financials

2026 *2027 *
Net sales 2.83M 2.46M 2.29M 2.1M 3.98M 269M 4.02M 27.01M 10.56M 135M 10.63M 10.4M 446M 20.09M 17.44M 16.26M 14.94M 28.25M 1.91B 28.56M 192M 74.94M 955M 75.43M 73.77M 3.16B
Net income -19.36M -16.81M -15.67M -14.4M -27.23M -1.84B -27.53M -185M -72.24M -921M -72.71M -71.12M -3.05B -19.89M -17.27M -16.1M -14.79M -27.98M -1.89B -28.29M -190M -74.22M -946M -74.7M -73.06M -3.13B
Net Debt - -
Logo TapImmune Inc
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company’s multi antigen recognizing (MAR)-T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad-spectrum anti-tumor activity. It is developing two product candidates, including an Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601) and an Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601 to recognize multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-